Scott Gottlieb was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
At Flagship Pioneering, Aram Adourian, partner, knowledge management, uses his skills to leverage internal and external knowledge and informatics across the breadth of the company’s research activities, as he tells LSIPR.
Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
The world of sequence variation IP is complicated and confusing, and fraught with legal risk, but there is a solution, as Ellen Sherin of GQ Life Sciences reports.
Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.